ICMR Advances New Vaccine Research for Zika, Flu, and Blood Cancer
ICMR’s Pioneering Vaccine Efforts
The Indian Council of Medical Research (ICMR) is set to revolutionize vaccine development with its recent partnership announcements. This initiative includes first-in-human Phase 1 trials for new vaccines against Zika, seasonal influenza, and therapies for blood cancer.
Collaborative Trials for Hope
In collaboration with Indian Immunologicals in Hyderabad, ICMR will develop a vaccine targeting the Zika virus, while working with Mynvax in Bengaluru for an influenza vaccine trial. Additionally, the apex body will engage with Aurigene Oncology on a molecule for treating multiple myeloma.
Expanding Cancer Research
Furthermore, ICMR signed an agreement with ImmunoACT for a CAR-T cell therapy study aimed at tackling chronic lymphocytic leukaemia. This effort underscores the ICMR’s commitment to enhancing clinical trial capacity across India, facilitated by premier institutions and centralized support.
- Strengthening India's clinical trial infrastructure.
- Developing indigenous molecules for effective treatments.
- Fostering public-private collaborations in health research.
Dr. Rajiv Bahl, Director General of ICMR, emphasized the importance of these advancements in ensuring affordable healthcare solutions for all.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.